dihydroguaiaretic acid has been researched along with Liver Steatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, YJ; Je, YT; Lee, BH; Lee, KY; Park, HJ; Park, S; Park, SJ; Shin, KJ; Sim, WC; Sung, SH; Yin, HQ | 1 |
| Hwang, JK; Kim, D; Kim, KJ; Lee, KE; Lee, MS | 1 |
2 other study(ies) available for dihydroguaiaretic acid and Liver Steatosis
| Article | Year |
|---|---|
LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
Topics: Animals; Base Sequence; Cell Line, Tumor; Diet, High-Fat; DNA Primers; Fatty Liver; Guaiacol; Humans; Lignans; Lipogenesis; Liver X Receptors; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Orphan Nuclear Receptors | 2014 |
meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Cell Culture Techniques; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyslipidemias; Enzyme Activation; Enzyme Inhibitors; Fatty Liver; Guaiacol; Hep G2 Cells; Humans; Hypolipidemic Agents; Insulin Resistance; Lignans; Lipid Metabolism; Liver; Molecular Targeted Therapy; Myristica; Non-alcoholic Fatty Liver Disease; Phosphorylation; Phytotherapy; Plant Extracts; Pyrazoles; Pyrimidines | 2011 |